Last reviewed · How we verify
Fluid balance
Fluid balance, marketed by Brugmann University Hospital, addresses general systemic symptoms and holds a niche position in the therapeutic market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market presence. The primary risk lies in the lack of reported revenue and key trial results, which may limit investor confidence and market expansion.
At a glance
| Generic name | Fluid balance |
|---|---|
| Sponsor | Brugmann University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- General systemic symptoms
- Swelling
- Bloating
- Digestive sluggishness
- Dizziness
- Headaches
- Muscle tension
Common side effects
Key clinical trials
- Virtual Reality for Postoperative Recovery After Major Abdominal Surgery (NA)
- Determining the Effects of Training on Nursing Students Using Two Different Methods for Maintaining Fluid and Electrolyte Balance in a Child Trapped Under a Collapse (NA)
- Nutrition for Precision Health, Powered by the All of Us (NA)
- Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness (NA)
- Gelaspan vs Crystalloid Therapy in Sepsis (PHASE4)
- Precision Resuscitation With Crystalloids in Sepsis (NA)
- Proactive Prescription-based Fluid Management vs Usual Care in Critically Ill Patients on Kidney Replacement Therapy (NA)
- Gravity in Flow: Automating Diuresis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluid balance CI brief — competitive landscape report
- Fluid balance updates RSS · CI watch RSS
- Brugmann University Hospital portfolio CI